<DOC>
	<DOCNO>NCT00617474</DOCNO>
	<brief_summary>The study hypothesis erythropoietin usage kidney transplantation , early phase , improve outcome patient graft increase patient graft survival .</brief_summary>
	<brief_title>The Effect Erythropoietin Usage Renal Function After Kidney Transplantation , Early Phase , Contrast Placebo Group</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Hb : &gt; 8 &lt; 10 gr/dl Age : &gt; 18 &lt; 55 year Cholesterol : &lt; 300 mg/dl Triglyceride : &lt; 400 mg/dl First Transplantation Protocol Immunosuppression : CSA + MMF + Prednisolone Systolic BP : &lt; 14 Diastolic BP : &lt; 9 History specify cardiac disease Second Transplantation Hb : &lt; 7gr/dl The patient need infusion blood Evidence local systemic infection , time EPO injection Presence ATN / DGF transplantation Presence emergent hypertension High risk patient ( Like ; PRA &gt; 50 % ) Past history hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>erythropoietin</keyword>
	<keyword>kidney allograft survival</keyword>
	<keyword>Recombinant Erythropoietin</keyword>
	<keyword>erythropoietin ( Epo ) -induced protein 29 , human</keyword>
</DOC>